Advancements in mass spectrometry (MS)-based clinical proteomics hold promise for improving diagnostic tests for cardiovascular disease (CVD) . Immunoassays, such as ELISA, are commonly used in a highthroughput clinical setting to quantify the concentration of serum protein biomarkers as a diagnostic tool [1, 2] . However, developing antibody reagents for quantitative ELISA assays can be a long and costly process [3] . In addition, the lack of standardization between ELISA assays and the susceptibility to several types of interferences caused by matrix effects, cross-reactivity, or nonspecific interactions, have been a common shortcoming [4] [5] [6] . ELISA assays coupled with fluorescence, imaging or laser-based detection measure nonspecific signals and cannot discriminate interferences and protein variants from the target protein [2] . However, MS can be a useful tool to achieve excellent specificity by directly measuring target proteins based on molecular mass and fragmentation patterns [7] . MS has been extensively used to study CVD-specific protein biomarkers owing to the high specificity, versatility for multiplexing and accuracy of the mass spectrometer [2, 5] . MS can be a useful tool for developing new methods to study disease mechanisms, validate and standardize ELISA assays, and discover novel biomarkers of CVD [8] .
Traditionally, immunoaffinity techniques have been the most common approach used to isolate CVD-related proteins from biofluids for subsequent MS detection. Immunoaffinity enrichment of protein biomarkers has several notable advantages to other conventional methods. The most significant attribute of immunoaffinity strategies is the ability to capture and concentrate target proteins with high specificity and recovery while eliminating the background noise caused by the complex biological matrix [9] . Specifically, magnetic-based immunoaffinity separation has been used widely, including our group, as an enrichment technique for proteins and other small molecules because it is a relatively fast, effective and gentle, in-solution Current trends in magnetic particle enrichment for mass spectrometrybased analysis of cardiovascular protein biomarkers future science group Review Schneck, Lowenthal, Phinney & Lee process that can be performed in parallel with multiple samples [10] [11] [12] [13] [14] [15] . The high surface area-to-volume ratio and tailored surface chemistries can enable high antibody loading in an effort to isolate and separate targeted proteins from complex human biomaterials. Several methodologies have utilized magnetic separation as an enrichment tool to characterize or validate cardiac-disease-related protein biomarkers by MS. This review focuses on the challenges of analyzing cardiovascular biomarkers by MS, the current approaches to separate and isolate CVD-specific protein biomarkers by magnetic separation, and future perspectives for immunoaffinity magnetic separation methods.
Protein biomarkers of CVD
CVD is one of the leading causes of death worldwide, causing an estimated 17 million deaths per year, primarily from heart attacks and strokes [16, 17] . Despite decades of scientific research and advancements in medical technology, prevention and diagnosis of CVD still remains a major challenge to the medical community. To date, several heart-tissue-specific markers associated with myocardial ischemia have been discovered and studied for clinical use. Some established CVD biomarkers include the cardiac troponins (cTn; subunits: cTnI/cTnT), C-reactive protein (CRP), B-type natriuretic peptides (BNPs), IL-33, IL-6, myoglobin and myosin light chain 1 [8, 18] . At elevated levels in the blood, these biomarkers have shown to correlate with CVD and can help diagnose cardiac injury. The primary diagnostic biomarker routinely used in the clinical setting is human cTn, a regulatory protein from heart tissue which is used as a marker for assessing cardiac damage and diagnosing myocardial infarction [19] . A summary of established cardiovascular biomarkers discussed in this review are outlined (Table 1) .
Most clinical blood tests use an antibody-based diagnostic assay, such as ELISA, to quantify cardiac-disease-specific protein biomarkers in serum to diagnose CVD; however, these immunoassays suffer from poor specificity and lack of interlaboratory assay standardization [20, 38] . Scientific development aimed to provide increasingly sensitive, specific and standardized assays for diagnosing CVD has led to many research studies. ELISA systems are currently used to perform clinical assays in hospitals for diagnosing CVD because the tests are practical, robust, fast and cost efficient compared with MS instrumentation, but MS can be a complementary tool for immunoassay development and validation since it can provide confirmation of protein discovery, unbiased target quantification and improved target specificity [1, 7] . Several reviews have compared the two platforms [5, [38] [39] . In this review, the focus is intended to demonstrate the need to use orthogonal approaches such as emerging magnetic particle enrichment strategies and MS to improve the performance of CVD-relevant ELISA-based measurements. Immunoaffinity coupled to MS-based proteomics approaches can be an alternative technique for validating candidate biomarkers for CVD [8] . For instance, quantitative targeted MS can be used to help establish reference measurement systems to achieve standardization and true metrological traceability to current clinical grade immunoassays [40, 41] . Analysis by isotope dilution (ID)-MS is considered the gold standard for protein or peptide quantification and is the preferred method for clinical validation of protein biomarkers. Measurements by ID-MS are more accurate and precise because the method requires the use of an isotopically labeled internal standard analogous to the target protein to account for sample processing and instrument variability [34, 40] . MS has the ability to distinguish the target protein from the isotopi- Table 1 . Established cardiovascular biomarkers studied by proteomic mass spectrometry-based methodology.
Tissue-specific biomarkers
Cardiovascular proteins Clinical utility Ref.
Biomarkers of necrosis Troponin
Diagnosis of AMI and risk stratification of heart disease [20] [21] [22] [23] [24] [25] [26] [27] [28] Myoglobin [29] Biomarkers of myocardial stress
Brain natriuretic peptides Aid in the diagnosis of heart failure [30] [31] [32] [33] N-terminal of the prohormone of BNP [32] Biomarkers of inflammation C-reactive protein Elevated levels correlate to cardiovascular risk [34] [35] [36] [37] IL-6, IL-33 [20, 32] AMI: Acute myocardial infarction; BNP: B-type natriuretic peptide.
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Current limitations for mass spectrometric analysis of cardiovascular proteins
MS has become an essential analytical tool within the clinical research laboratory setting and has been a useful tool to provide additional information on existing cardiac-related protein biomarkers [8] . In particular, the unique capabilities of multiple reaction monitoring (MRM) or selected reaction monitoring (SRM) have further improved the high specificity and accuracy of the mass spectrometer [42, 43] . Detection by liquid chromatography (LC) coupled with tandem MS (MS/ MS) can distinguish target peptides directly by retention time on the LC column, and based on the precursor and fragment mass-to-charge ratio values of the peptide; thus, achieving high specificity [5] . Despite continuing improvements in MS technologies, developing MS-based quantitative assays for low-abundant protein biomarkers is still a substantial challenge due to the limited sensitivity and small dynamic range of the mass spectrometer. There are several obstacles that limit the detection and quantification of low-abundant proteins in biological matrices using MS-based proteomic technologies. First, tissue leakage proteins, such as cTn, are typically present at extremely low concentrations making it difficult to enrich quantifiable levels from the blood for analysis by targeted MS. Tissue leakage proteins act as important diagnostic markers because they normally function within the cardiac tissue cells [44] . After myocardial necrosis, tissue leakage proteins related to CVD can be released into the bloodstream from damaged heart muscle tissue. The elevated protein concentration found in blood can indicate the amount of cell damage for diagnostic evaluation [44, 45] . For example, cTn is nearly unquantifiable by targeted MS when analyzed in normal human serum from healthy donors, but the protein levels are slightly elevated (≈1-5 ng/ml) in sera of people who have suffered from myocardial trauma [46] . This slight, but significant, elevation of cTn levels in serum may be quantified by MS, but only if cTn can be effectively isolated from the background serum matrix.
Furthermore, many CVD-related proteins present as modified forms or isoforms in blood make it difficult to target, characterize or quantify these structural differences. For example, cTn is known to be heterogeneous in the bloodstream after a myocardial infarction, and this heterogeneity has been known to cause variations among ELISA and other sandwichimmunoassay measurements [47] . There have also been several studies reporting that BNP circulates in the bloodstream in various forms, which can influence the diagnosis of heart failure [30, 31] . Characterization studies of these modified proteins can potentially provide useful structural information regarding particular CVD states [21, 48] .
The complexity and the dynamic range of proteins found in biological samples, such as human plasma or serum, also severely hinder the detection of lowabundant proteins for quantitative MS platforms. Plasma consists of thousands of proteins and protein isoforms with the dynamic range of the protein concentrations spanning greater than 10 orders of magnitude, ranging from mg/ml levels to pg/ml levels [44, 49] . Approximately 99% of the total human plasma proteome is dominated by the top 22 most abundant proteins, with the remaining 1% consisting of lowabundant proteins [8, 44, 49] . For instance, albumin and IgG account for nearly 55 and 17% of the plasma proteome by mass, respectively [44, [50] [51] . These high abundant proteins have a tendency to dominate MS detection signals and mask the detection of lower abundant proteins [44, 49] .
Without effective isolation strategies, quantitative protein measurements in biological matrices can typically only be useful in the range from 100 to 1000 ng/ml when analyzed with LC coupled with triple quadrupole (QQQ) mass spectrometers in the SRM mode [1, 8, 38, 52] . With improvements to MS instrumentation and incorporation of protein enrichment, limits of detection (LODs) for MS-based protein quantification have been significantly lowered. Strategies incorporating immunocapture coupled with targeted MS are currently capable of quantifying proteins from biofluids with limits of quantification (LOQs) in the ng/ml range [20, 38] . However, at normal levels, protein biomarkers of cardiac disease typically range from ≈0-5 pg/ml (cTn and IL-6) to 1000 ng/ml (CRP) in plasma [34, 44, 53] . CVD-related proteins in the lower concentration range are below the LODs for current MS instrumentation using targeted and nontargeted proteomic approaches [34, 44, 54] . Currently, the most sensitive quantitative MS platform used in the proteomic field uses chromatographic systems operating in the nl/min realm coupled with MRM-MS detection [10] . Compared to MS techniques, sandwich-ELISA assays with subsequent amplified detection are a more sensitive platform and have achieved LOQs in the low pg/ml range for protein quantification [38, 53, 55] Traditional enrichment strategies for CVD-related protein biomarkers Traditionally, fractionation, immunodepletion and affinity enrichment schemes not involving magnetic particles have been used to limit interferences and reduce the dynamic range of biofluids for improved MS analysis. Using these other nonmagnetic particle-based enrichment methods, targeted proteins can be isolated from complex matrices and concentrated prior to analysis. For instance, immunodepletion and strong cation exchange chromatography (SCX) have been used to reduce the complexity of serum in a multiplexed, quantitative analysis of CVD-related biomarkers. Keshishian and coworkers [32] depleted high abundant proteins from serum using commercial, immunoaffinity depletion columns. Subsequently, the depleted serum samples were fractionated using SCX to concentrate cardiovascular biomarkers and analyzed by targeted MS for cross validation studies. Some of the CVDrelated proteins analyzed included CRP, troponin I, troponin T, BNP and IL-33. Using SCX fractionation and depletion strategies lowered LOQs to the ng/ml levels. Generally, immunodepletion strategies improve specificity, but at the cost of low sample throughput, reduced protein recovery and the introduction of higher variability in measurements [1, 32, 57, 58] .
Affinity chromatography using agarose beads is another protein enrichment approach to isolate CVD biomarkers from biomaterials [22] [23] [24] [25] . Ge's group [23] [24] [25] enriched cTn using affinity chromatography to study CVD mechanisms. Cyanogen-bromide-activated Sepharose immobilized with antibody was used to selectively isolate cTn from heart tissue. The purified protein marker was analyzed by top-down MS to probe the role of phosphorylation of the biomarker and provide further CVD insights. Sepharose varies in shape and size (40-65 μm diameters) and has a porous structure. However, for low-abundant protein enrichment, the porous structure of Sepharose may be unfavorable because of potential protein entrapment, which could cause nonspecific binding or loss of antibody activity if not extensively washed and centrifuged [59] [60] [61] .
In another study, Kiernan et al. [29] developed a multiplexed mass spectrometric immunoassay to analyze myoglobin, an established biomarker for myocardial infarction, and two novel CVD-related biomarkers, amyloid A1α and S-sulfated transthyretin, from plasma samples. To isolate these three cardiovascular markers, multiplexed affinity pipets were used. Antibodies for each protein target were coupled by carbonyldiimidazole chemistry to the activated porous affinity supports inside the pipets. Using the derivatized-affinity pipets, the CVD-related proteins were captured, eluted off the inside of the pipet and then analyzed by matrix-assisted laser desorption ionization time of flight MS (MALDI-TOF MS). However, the resulting immunoassay followed by MALDI-TOF MS was only able to detect myoglobin levels above the typical clinical cutoff values (≈100 ng/ml). Niederkofler et al. [33] also used immunoaffinity pipettes to extract BNP from plasma of patients with heart failure for subsequent MALDI-TOF MS analysis. Using this approach, a lower LOQ of 3.1 pmol/l was achieved for quantifying BNP in plasma.
In another case, Anderson's group [10] initially implemented nanoliter-capacity columns immobilized with antipeptide antibody for enrichment of low-abundant peptides. This quantitative method, first reported by Anderson and colleagues [62] , is termed 'stable isotope standards and captured by antipeptide antibodies' (SIS-CAPA) to describe the process which uses antipeptide antibodies to isolate target peptides and corresponding isotopically labeled peptides from a tryptic digestion. However, some disadvantages with using affinity nanocolumns included sample-to-sample carry-over after column regeneration, concerns with binding kinetics and limited multiplexing for higher throughput validation studies. Anderson's group later used magnetic beads as an alternative antibody solid phase [10] .
Current platform: magnetic particles used as a substrate for immunoaffinity enrichment Functionalized magnetic particles (or beads) have attracted widespread attention in the proteomics field due to their ability to preconcentrate low-abundant proteins and peptides for MS analysis [63, 64] . Magnetic iron oxide particles have been researched for diagnostic applications because of their unique chemical, physical and magnetic properties, which include variable surface engineering, small size (1 nm-5 μm), lack of porosity, ease of preparation and ability to be magnetized [65] . Most superparamagnetic particles, which are magnetic only in the presence of an external magnetic field, have been extensively used for immunoassays because their magnetic properties can be used to selectively separate proteins from complex samples. Magnetic particles conjugated with antibodies or other capture agents can mix homogenously with biological matrices in the absence of an external magnetic force since there is no magnetic remanence for the particles to attract to each other [66] . During the mixing process, the particles coated with antibodies can selectively capture antigens and be isolated from the rest of the sample using a magnetic separator; thereby, purifying and enriching the target analyte for subsequent MS detection (Figure 1 ) [38, 62, 67] . Due to these excellent characteristics, magnetic particles have been favorable for biological separation. Immunoaffinity with magnetic particles can be performed by targeting protein or peptides for enrichment; followed by preparation for mass spectrometry-based analysis. Workflow A entails capturing target proteins from biofluids by using antiprotein antibody. Workflow B entails capturing target peptides from a tryptic digestion of biofluids. Magnetic particles can be either synthesized in the laboratory or commercially purchased from a variety of manufacturers [68, 69] . Paramagnetic particles typically have a magnetic iron oxide core with a polymer or silica shell on the outer surface. The nonmagnetic outer coating serves to protect the biological target from any toxic exposure caused by the metal oxide core, and it also provides surface functional groups needed for different bioconjugation methods [69] . Magnetic particles can be functionalized using surface chemistry to bear various functional groups, such as amino, carboxyl, tosyl or hydroxyl groups, which can further be utilized to activate coupling mechanisms for antibody loading [3, 69] . Through a variety of coupling schemes, particles can also be immobilized with affinity ligands such as antibodies, streptavidin, biotin, protein A and protein G, which is more common for protein and peptide immunoaffinity [69] .
With a wide variety of magnetic materials and bioconjugation methods, selection of a magnetic particle system with high antibody coupling efficiency is an important factor when developing enrichment protocols. Whiteaker et al. [3] evaluated seven magnetic particles, each with a different surface chemistry, to determine which functionalized type and conjugation method would provide the highest capture efficiency of targeted biomarkers for their immunoassays. The magnetic particles were compared and evaluated to determine which one exhibited the highest antibody loading, showed enhanced binding activity (oriented vs non-oriented immobilized antibody) and exhibited low nonspecific binding. Assessing magnetic particles and bioconjugation schemes to prepare highly active antibody-magnetic particle conjugates is essential, especially when low-abundant biomarker enrichment and MS-based sensitivity must be optimized.
Micrometer-sized magnetic particles used for immunoaffinity separation Microbeads, such as Dynabeads ® (Invitrogen, CA, USA), are often used as the immunomagnetic carrier for capturing protein biomarkers from complex biomaterials because microbeads are commercially available with different surface functionalities for facile attachment of antibodies [20, 34, 51, [69] [70] [71] . For example, Kilpatrick and Bunk [34] used microbeads to isolate spiked CRP in human serum for developing an MS-based reference measurement procedure. CRP was quantified by a bottom-up targeted proteomic approach using an LC-QQQ-MS instrument operating in MRM acquisition mode, combined with ID and standard addition methodologies. In this CRP study, nonspecific binding future science group Review Schneck, Lowenthal, Phinney & Lee caused by the microbeads was also assessed during the bead assay. As a negative control set, the microbeads were conjugated with bovine serum albumin instead of CRP monoclonal antibody (mAb). Negligible nonspecific binding was shown in the control set of the microbeads. Nonspecific adsorption of proteins onto immunomagnetic carriers is a general factor that must be considered when developing immunoassays on a bead platform.
Another magnetic bead-based assay coupled with targeted MS was developed by Berna et al. [71] to study myosin light chain 1 as a protein biomarker for drug-induced cardiac injury. Myosin light chain 1 was captured from diluted, immunodepleted rat serum by using streptavidin Dynabeads conjugated with mAb. For bottom-up MS, the captured proteins were digested with trypsin while still conjugated to the magnetic bead. In this process, the antibody-antigen complexes were dissociated and the proteins were eluted off of the magnetic particles. After digestion, the digest supernatant was recovered by isolating the beads using a magnet. Using an isotopically labeled peptide internal standard, Berna et al. quantified the concentration of myosin light chain 1 in rat serum by tandem MS analysis.
In another study, Lowenthal et al. [70] used ID-LC-MS/MS methodology to evaluate the binding constants for a panel of anti-cTnI mAbs after conjugation to microbeads. In this work, tosylactivated microbeads conjugated with six pre-screened candidate anti-cTnI antibodies were utilized to capture cTn. Samples were digested and peptides were analyzed by LC-MRM-MS/MS using isotopically labeled peptides as internal standards to measure relative binding affinities. Determining the efficiency of antibody capture toward different antigens is critical to consider when optimizing immunoaffinity purification strategies. Currently, there is diversity in the quality and selectivity of commercially available antibodies directed toward CVDrelated protein markers [47] . Due to the multitude of antibodies that can target different regions of proteins, immunoassays with different capture antibodies can result in disparate protein measurements. Determining which antibody has a strong binding affinity for its antigen with low nonspecific binding can help improve immunocapture development, especially for low-abundant protein enrichment [26, 70] .
Microbeads have also been used as an immunoaffinity support for developing enrichment methods at the peptide level prior to MS analysis. The gold standard in absolute quantitative MS-based measurements of proteins incorporates the use of an intact, stable isotope-labeled protein as an internal standard for all sampling steps and for MS analysis. When intact isotope-labeled protein analogs can be obtained for use as internal standards, they should be spiked into the sample at the earliest possible point in the sample preparation procedure. However, due to various technical challenges, isotopically labeled protein analogs are difficult to produce [34, 71] . As an alternative strategy, when only stable isotope-labeled peptides are available as internal standards, or when auto-antibody interference exists, or if the enrichment of the measurand is improved at the peptide level compared with its native protein, antipeptide antibodies can be utilized to capture and enrich proteotypically generated peptides and their isotope-labeled analogs spiked into the sample digest. Labeled peptides can be spiked into the sample after digestion and be used to account for any potential sample preparation losses during immunocapture and MS analysis for more precise quantification measurements [34] . Interferences due to endogenous autoantibodies are generally a concern for antiprotein antibody-based immunoassays. Therefore, digestion of the target protein before immunoprecipitation can reduce nonspecific binding of interferences caused by endogenous proteins and auto-antibodies found in biofluids. Auto-antibodies have been observed to interfere with the measurement of many commercial cTnI immunoassays for diagnosing myocardial infarction [27, 28] . Peptide enrichment coupled with MS analysis can reduce auto-antibody competition and can help cross-validate ELISAs that may be subject to these interferences.
Kuhn et al. [20] demonstrated that peptide immunoaffinity enrichment coupled with ID-MS could be used to quantify cTnI in plasma from patients who underwent a planned myocardial infarction, a treatment for hypertrophic obstructive cardiomyopathy. Microbeads immobilized with antipeptide polyclonal antibodies were added to the peptide sample for capture studies. The bead samples were then analyzed by nanoLC-MRM-MS. Troponin I and IL-33 standard proteins spiked into 20-50 μl plasma volumes were measured using a linear calibration curve ranging from 1.5 to 5000 ng/ml with satisfactory precision and reproducibility. By this methodology, Kuhn et al. was able to demonstrate that multiplexed SISCAPA-MRM assays can be used as an alternative to help cross-validate ELISA and other sandwich-immunoassays. Using peptide immunoaffinity strategies, enrichment can be enhanced by up to three orders of magnitude, resulting in lower LODs and LOQs for MS analysis [1, 20] .
Recent technology developments in magnetic particle enrichment
Immunoaffinity-based proteomic assays are being developed so that they can be integrated into clinical laboratories for routine high-throughput verification An array of 96 magnetic pins can be placed inside of disposable tip combs to transfer magnetic particles between well plates placed on a sample carousel. A platform consists of a beads plate, a magnetic pin-head plate, a tip plate, a sample plate containing the peptides, a few wash plates, and an elution plate. The magnetic pins can be detached from the tip comb, allowing the tip comb to also serve as a mixing tool. Adapted with permission from [72] ; © 2009 American Chemical Society.
future science group Current trends in magnetic particle enrichment for MS-based analysis of CVD protein biomarkers Review studies. Automated magnetic separation plays a crucial role in these large-scale studies and is currently being industrialized to help standardize sample processing protocols. One technology, the KingFisher™ magnetic bead processor (Thermo Fisher, MA, USA) (Figure 2) , was originally developed to provide a platform by automating large-scale, magnetic processing for nucleic acid samples, and later was employed for automated protein/peptide enrichment. Ficarro et al. [72] utilized the KingFisher as a robotic platform for phosphopeptide enrichment. The KingFisher provided a reproducible platform for phosphopeptide purification with the additional benefit of speed due to the parallel enrichment processing. A magnetic bead processor was also used to develop partially automated, multiplexed SISCAPA-MS methods to reproducibly quantify proteins in plasma [73] [74] [75] . Each of these reports showed that using automated bead capture and washing after peptide-immunoaffinity enrichment reduced sample handling and provided acceptable assay reproducibility. The automatized magnetic bead technology was shown to improve throughput and provide the necessary performance needed for large clinical studies.
One disadvantage to using an offline magnetic bead processor is the possibility of peptide loss after the elution plate wash and before LC-MS/MS analysis. A magnetic bead trap was later developed for highthroughput settings to perform in-line with nanochromatographic systems, followed by MS detection. Anderson et al. [10] used microbeads as the immunoaffinity carrier during the immunoprecipitation assay. However, to further improve recovery of the captured peptide, the subsequent wash and elution steps were Most studies reported for CVD protein capture and MS detection have been performed using microbeads. However, using magnetic beads smaller than 1 μm in diameter may achieve higher capture efficiency due to their relatively higher surface area-to-volume ratio [9] . There has been much interest in developing synthetic methods to produce high-quality iron oxide nanoparticles to further improve immunomagnetic separation processes. Since nanoparticles (10 -9 m) are three orders of magnitude smaller in diameter compared with microparticles (10 -6 m), surface area-to-volume ratios can increase 100-1000-fold, which can correlate to higher protein adsorption [3, 35] . Synthesis protocols for iron oxide nanoparticles, such as by coprecipitation, solvothermal and hydrothermal methods, are relatively well established and can be found in several reviews [65, [76] [77] [78] .
In one case, Chou and coworkers [35] developed a methodology known as nanoprobe-based affinity mass spectrometry (NBAMS) and demonstrated the advantages of using magnetic nanoparticles (MNPs) for multiplexed immunoassays. Nanoparticles were synthesized by coprecipitation, and were then coated with silica. Afterward, the silica-coated MNPs were functionalized with an amino-silane and crosslinked with bis(hydroxysuccinimide ester) prior to antibody immobilization. The average diameter of the MNPs was 9.7 nm. The nanoparticles were used as a nanoprobe to preconcentrate proteins, such as CRP, from unfractionated human plasma. Afterward, the samples were mixed with an ionization matrix for subsequent MALDI-TOF MS analysis (Figure 3) [36] . The authors compared the extraction efficiency and detection specificity using microbeads (2.8 μm) versus nanoparticles, and the nanoparticles showed superior MS results compared with the microbeads (Figure 4) [35] .
Wang and colleagues [36] used the NBAMS method for a multiplexed immunoassay followed by direct MALDI-TOF MS analysis to profile and quantify multiple biomarkers. For the immunoaffinity assay, three kinds of antibody-conjugated MNPs were prepared and then mixed together with human serum to capture three marker proteins, one being CRP, to demonstrate that several biomarkers could be used to predict CVD in one, multiplexed immunoassay. After capturing the targeted biomarker proteins, the nanoparticles were isolated using a magnet. The resulting samples were mixed with matrix and spotted on the MALDI plate using the seed-layer method, which future science group Current trends in magnetic particle enrichment for MS-based analysis of CVD protein biomarkers Review homogenously coated the plate with bead sample for more reproducible results. An internal standard was also mixed with the sample and matrix for quantitative purposes. Using this method, captured proteins were released from the MNPs when mixed with the acidic and organic MALDI matrix, which prohibited the nanoparticles from interfering with the MS detection. Without the elution step prior to MS detection, potential sample loss was reduced, therefore improving assay sensitivity and accuracy [35] [36] [37] .
Lin et al. [37] focused on orienting antibodies onto the nanoparticles to increase immunoactivity by optimizing exposure of the antigen-binding sites for improved capture efficiency. To fabricate oriented immobilization, functionalized nanoparticles can be linked to the antibody through localized groups which are distant from its biologically active sites. One approach can be to immobilize an antibody through its carbohydrate residues in the Fc constant region using boronate formation, as Lin and coworkers described. That group also compared self-and random-oriented antibody conjugation schemes. The self-oriented immobilized antibody-MNP conjugates significantly increased capture efficiency when targeting proteins at low concentrations. Overall, the self-oriented antibody-MNP conjugates always demonstrated better extraction efficiency compared with random immobilized antibody-MNP conjugates. Surface blocking and pH stability of the antibody-MNP conjugates were also investigated for enhanced immunomagnetic activity.
In another study by Zhang and coworkers [79] , MNPs were synthesized by chemical coprecipitation and were shown to average 18 nm in diameter. The nanoparticles were coated with meso-2,3-dimercaptosuccinic acid to bear a carboxyl functional group to immobilize anticTnI antibody using an carbodiimide-coupling method. The immunomagnetic nanoparticles were evaluated to determine the amount of antibodies immobilized, the activity and the stability of the antibody-MNP conjugates. Zhang et al. focused on the optimization of the antibody-MNP conjugates but did not perform MS analysis after immunocapture. Rather, the success of the anti-cTnI antibody-MNPs conjugates was verified by testing immunocapture efficiency with ELISA.
Conclusion
In this review, we have highlighted the current immunomagnetic separation techniques that have been utilized to help enhance biological MS detection for cardiovascular biomarkers. Optimizing magnetic particle-based immunoaffinity techniques is essential for capturing low-abundant protein biomarkers in biological samples and achieving improved MS signal-to-noise ratios. Several techniques can be used to immobilize antibodies to the surface of modified magnetic particles. When preparing antibody-magnetic particle conjugates, some factors to consider include choosing highly active antibodies, evaluating antibody loading with different conjugation schemes and reducing nonspecific binding issues. Most reported studies use microsized particles for immunocapture; however, MNPs hold promise by providing higher capture efficiency due to their large surface area-to-volume ratio. Magnetic particle enrichment is continuously improving as new technologies are being developed to help standardize protocols for high-throughput studies within clinical laboratories. Review Schneck, Lowenthal, Phinney & Lee immunoaffinity strategies have the potential to enrich and purify low-abundant target proteins from complex biofluids, limit interferences and reduce the dynamic range of an enriched sample preparation. Improvements in the development and production of antibodymagnetic particle complexes with low background binding are needed to enrich low-abundant proteins of clinical relevance. Microbead-based separation and technology is a widely established strategy in many research laboratories. However, extensive research toward developing MNPs at a large scale for commercialization is underway and will slowly begin to replace microbeads for future separation approaches [80] . Currently, limited work has been published using MNPs for immunoaffinity strategies in MS-based proteomic studies. Synthesized MNPs can offer larger surface area-to-volume ratios that may result in higher protein adsorption. Therefore, it may be beneficial to use MNPs with larger surface areas for future enrichment studies. For MNPs to be of practical use for immunocapture, they must exhibit high dispersability in aqueous buffered samples, maintain strong magnetic properties and have small, spherical sizes (sub-100 nm) with very little size variability. New magnetic-based technology and materials will need to be implemented over the next several years to advance discovery and validation developments for cardiovascular and other clinical disease-relevant biomarkers.
There is also potential to use other reagents for immunoaffinity enrichment and MS-based quantification. Antibodies are the preferred biomolecule for immunocapture due to their high affinity and antigen selectivity. Nevertheless, specific antibodies require long development times and are relatively expensive [81] . Affinity molecules other than antibodies, such as aptamers, may be used for capturing proteins from complex matrices. Slow-off-rate modified aptamers (SOMAmers) are currently being applied to the proteomic field in a non-MS-based detection platform [82, 83] . The unique aptamers, which can be synthesized faster compared with antibody production, may increase capture efficiency for some clinically relevant proteins.
Particularly for protein quantification using LC-MS/MS, there is a continuing need for the production of recombinant isotope-labeled proteins in place of labeled peptides. Protein measurements are more accurate and precise when an isotopically labeled intact protein is used to account for digestion variability and any protein losses during the sample preparation. Producing intact isotopically labeled proteins to use as internal standards is challenging because of expression difficulty, protein modifications and truncations. Recently, quantification studies using LC-MS/MS have been described that use isotopically labeled quantification concatamers (QconCAT) as internal standards to account for some digestion variability. A QconCAT construct allows for many peptides to be expressed and purified from a custom DNA sequence that contains unique tryptic peptides of the target protein [84] . The QconCAT approach adds flanking regions to help produce a construct that can somewhat mimic the target protein. During the digestion process, the labeled peptides can be separated from the flanking regions and released as internally labeled peptides for quantification purposes [84, 85] . Until new strategies and technologies become available to produce recombinant, isotopically labeled intact proteins, QconCAT constructs may be a more useful internal standard than labeled peptides for CVD-specific protein biomarker quantification by LC-MS/MS.
Multiplex assays, such as Luminex ® (Biorad, CA, USA), have proven to be a useful tool to simultaneously quantify multiple cardiovascular-related biomarkers to study CVD mechanisms [86] . The Luminex technology is a multiplexed system that combines sandwich-immunoassays involving distinctive colored beads with fluorescent dyes and flow cytometry. Multiplexed MS-based proteomic studies involving the enrichment of multiple CVD-related proteins concurrently can also be useful for efficient ELISA validation and other diagnostic evaluations, including these new multi-detection technologies such as Luminex. Sets of magnetic particles can be conjugated with unique antibodies specific for various CVD-specific proteins in a multiplexed immunoaffinity strategy. This multimarker concept using MS detection has been proposed by others, but yet, little work has been published and has not been regularly implemented in clinical research laboratories [8, 38] . For multiplexing to be used in future MS-based proteomic studies, advancements in immunoaffinity enrichment and labeled reagents are needed. Simultaneous analysis of a panel of biomarkers could significantly improve CVD diagnosis in the future.
Magnetic-based immunoaffinity strategies and MS detection are proving to be a powerful combination for protein biomarker analysis and are becoming more reputable as advancements in MS instrumentation, magnetic materials and automatized technology continuously progress. MS can act as a tool to complement ELISA assays by overlaying data with existing or new protein biomarkers to validate assays. Even with the progress of LC-MS/MS and existing automation systems for magnetic particle-based separation, implementation of LC-MS/MS instrumentation into the daily workflow of current clinical laboratories and hospitals is still a longshot away. Compared to ELISA-based systems, the application of LC-MS/MS in clinical medicine is cur-future science group Current trends in magnetic particle enrichment for MS-based analysis of CVD protein biomarkers Review rently very expensive due to instrumentation and the need for highly trained personnel to run and maintain LC-MS/MS instruments [7] . Yet, many highly specialized laboratories and LC-MS/MS manufacturers are continuously refining magnetic biomaterials and enrichment protocols, developing automative sampling systems, and improving the sensitivity of the LC-MS/MS instrumentation to achieve robust, accurate and precise measurements needed for clinical testing.
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Execeutive summary
• Proteomic analysis by antibody-based assays and mass spectrometry (MS) has provided valuable clinical information by identifying and quantifying cardiovascular-specific biomarkers to help understand health status.
• Challenges for MS technology include small dynamic ranges, poor sensitivity and slow throughput; therefore, enrichment strategies are needed to overcome these technicalities.
• Fractionation, immunodepletion and agarose-based immunoaffinity strategies all have trade-offs in isolating cardiovascular biomarkers from biological samples, but magnetic separation has demonstrated its capabilities as an affinity assay to provide excellent and rapid enrichment performance for low-abundant cardiovascular proteins.
• The high surface area-to-volume ratio and magnetic property of magnetic particles make them an ideal carrier for efficient, parallel, antibody-based enrichment to capture cardiovascular proteins: -Magnetic particles can be modified and immobilized with antibodies and other biomolecules by a variety of conjugation schemes; therefore, it is important to evaluate different antibody-magnetic particle conjugates to optimize immunoaffinity protocols; -Micrometer-sized magnetic beads have been commonly used for immunoaffinity strategies because they are commercially available with different surfaces coatings and have small size variability; -Magnetic particle-based automated technologies are being developed to help standardize sample processing protocols and improve routine high-throughput studies within clinical laboratories; -Nanometer-sized magnetic particles offer higher binding surface area-to-volume ratio and should be more beneficial for low-abundant biomarker enrichment or studies with limited sample volumes.
• New solutions to enhance MS sensitivity for cardiovascular biomarker analysis include using smaller magnetic particles within the nanometer range, investigating other potential bioaffinity capture agents and labeled reagents, and working toward developing more multiplexed analyses of biomarker panels for higher enrichment efficiency and throughput.
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